In order to make clear the characteristic biological properties of IL-la, its protective capabilities on bacteria-induced and LPSinduced lethality were compared with other BRMs in BALB/c mice. Pretreatment with IL-la (i.p., s.c.) or OK-432 (i.p.), could protect mice from the lethality of a K. pneumoniae infection (i.p. ), and pretreatment with IL-la or TNF a could protect mice from LPS (i.p.) lethality. IL-la could protect mice from both bacteria-and LPS-induced lethality. There was no difference in serum corticosterone levels after the LPS injection between the IL-la pretreated and untreated groups. However, a more rapid clearance of LPS from the serum and a stronger LPS-neutralizing activity in serum were observed with the LAL assay in IL-la pretreated mice than in untreated mice. The enhanced LPS-clearance was suggested to be partly responsible for the increased protection against LPS-lethality. IL-la was indicated to be a unique BRM and to become a useful tool for the prevention of life-threatening bacterial infections and subsequent endotoxin shock.
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IL-la ; infection ; LPS ; BRM A variety of biological activities of interleukin-1(IL-1) has been reported by many investigators (Dinarello 1984; Oppenheim et al. 1986 ), these being induction of fever and somnolence, lymphocyte activation, induction of acute-phase reactants, augmentation of bone marrow cell proliferation, stimulation of the pituitary-adrenal axis, enhancement of resistance against infections, radioprotection, etc. Among the biological activities of IL-1, the enhancing effect of IL-1 on resistance against infections is of practical interest for medical oncologists, because infection is a serious problem in patients who receive intensive anticancer therapies. In a previous report (Morikage et al. 1990 ), we showed that IL-1a could enhance anti-bacterial resistance in anticancer drug-treated hosts as well as in normal ones. In further studies on mechanisms for the enhanced antibacterial resistance by IL-la, we found that IL-1a could also protect mice from LPSlethality. But the same effect on LPS-lethality was not observed with OK-432, in spite of having the activity to enhance antibacterial resistance. Therefore, we compared the protective capabilities against bacteria-induced and LPS-induced lethality of IL-1a with other BRMs hoping that we might make clear the characteristic properties of IL-la.
The present study suggested that IL-la might have unique biological activities distinct from other BRMs.
MATERIALS AND METHODS
Animal. Male BALB/c mice were obtained from Nippon SLC, Hamamatsu, Japan. The experimental mice were 8 to 12 weeks old and weighed 20 to 25 g.
Biological response modifiers. Recombinant human interleukin-1 alpha (IL-la ; LAF activity, 2.26 X lo' U/mg protein) (Nakamura et al. 1986 ) and recombinant human tumor necrosis factor alpha (TNFa, 3 x 106 U/mg protein) (Sohmura et al. 1986 ) were provided by Dainippon Pharmaceutical Co., Ltd., Osaka, and OK-432 (Mizushima et al. 1988 ) by Chugai Pharmaceutical Co., Ltd., Tokyo, recombinant human interleukin-1 beta (IL-lb ; LAF activity, 2 X 10? U/mg protein) (Kikumoto et al. 1987 ) by Otsuka Pharmaceutical Co., Ltd., Tokushima, human recombinant interleukin-2 (IL-2 ; 5 x 10' U/mg protein) and lentinan (LNT) (Chihara et al. 1969 ) by Ajinomoto Co., Ltd., Tokyo, murine recombinant interferongamma (IFN-y ; 5 x 106 U/mg protein) by Shionogi Pharmaceutical Co., Ltd., Osaka, recombinant interferon alpha A/D (IFN-a ; 2 X 108 IU/mg protein) by Nippon Roche Inc., Kanagawa and sizophyllan (SPG) (Norisue et al. 1980 ) by Kaken Pharmaceutical Co., Ltd, Tokyo. One KE of OK-432 contains 0.1 mg of dried streptococci and 2,690 units of penicillin G, and does not contain endotoxin. The endotoxin contents of IL-la and TNFa preparations are 0.3-0.4 ng/mg of protein. These BRMs were dissolved in a 0.85% NaCI solution just before use. Each BRM was given on days -6 and -2, or on days -4 and -2 .
Bacteria and LPS inoculation. Klebsiella pneumoniae was cultured in a heart-infusion broth medium containing 1% glucose. The bacterial suspension or LPS (Salmonella typhosa 0901; Difco Lab., Detroit, MI, USA) was inoculated ip on day 0 in all experiments. Animals that survived more than 7 days after the challenge were regarded as survivors.
Measurement of LPS level in serum. Serum LPS level was determined by a modified turbidimetric kinetic assay using Limulus amoebocyte lysate (LAL). The principle of the assay was described by Oishi et al. (1988) . Briefly, blood was collected aseptically from orbital vessels of anesthetized mice 1, 3, 6, and 12 hr after LPS (S. typhosa 200,ug) i.p. injection, and the serum was diluted 10,000-fold with pyrogen-free distilled water. The diluted serum sample (100 ,u l) was admixed with an equal volume of reconstituted LAL (Wako Pure Chemical Industries Ltd., Osaka, manufactured by Associates of Cape Cod Inc., Wood Hole, MA, USA) in a 96-well microtest III plate (Falcon 3072) and then incubated at 3TC. The turbidity change in the gelation response of LAL was measured every 10 min with a microplate spectrophotometer at 405 nm of optical density (O.D.). Each data was plotted, and the gelation time to reach 0.25 at O.D. 405 was calculated. Then, the LPS concentration was calculated according to the standard curve for the LPS concentration.
In vitro LPS-neutralizing activity in serum. The LPS neutralizing activity in serum was measured by the method as described by Novitsky et al. (1985) with minor modifications. Briefly, blood was collected aseptically from orbital vessels, and serum was frozen at -80°C until use in pyrogen-free tubes. In the LAL assay, serum sample (50,ul) was added to an equal volume of serially diluted LPS (S. typhosa) solution in a 96-well microtest III plate. After incubation of the plate for 3 hr at 3TC,100,ul of the reconstituted LAL was added, and the turbidity was measured every ten min for 60 min as mentioned above. The O.D. 405 at 60 min incubation was plotted, and the concentration of LPS needed for producing a 50% LAL-gelation response (LR50) was calculated.
Measurement of the corticosterone level in the serum. Blood was collected from orbital vessels 0, 1, 3, 6 and 12 hr after LPS S. typhosa (200 pug) i.p, injection. Steroids in the serum were extracted with a C18-cartridge (SEP-PAK ; Waters Associates, Milford, MA, USA) according to the package instructions. Methanol was evaporated in vacuo at 37°C, and then the residue was dissolved with 100,1 of 99.7% methanol for high-performance liquid chromatography (HPLC). Corticosterone in the sample was determined with HPLC as described by Shimazu et al. (1983) . Briefly, a Shimazu Model 6A chromatograph with a Shimazu Model SPD-2A Uv detector and a stainless-steel column (25 cm x 4.6 mm) packed with reversed-phase Nucleosil 7018 (Chemco Co. Ltd., Osaka) were used. The mobile phase was acetonitrile-2% acetic acid solution (40: 60). The column temperature was 40°C, the flow rate 1.0 ml/min, and detection wave length 254 nm. The peak area was measured using a Shimazu C-R3A computing integrator. As a standard sample, corticosterone (No. 0-2505; Sigma Chemical Co., St. Louis, MO, USA) was used.
Statistics. Numbers of surviving mice were statistically evaluated by the Fisher's exact test and other results by the Student's t-test.
RESULTS

Protective capability of IL-la to bacterial infection in comparison with other BRMs
In order to evaluate roughly the protective capability of IL-1t to bacterial infection, it was compared with various kinds of BRMs in BALB/c mice. Each BRM was administered on days -4 and -2, and K. pneumoniae (2 x 108 cfu) was inoculated i.p. on day 0. As shown in Fig. 1 Protective effect of IL-la on LPS-induced lethality Since IL-la (i.p., s.c.) and OK-432 (i.p.) showed a protective effect on K. pneumoniae-induced lethality, further examinations were made to see if they could protect mice from LPS-induced lethality. As shown in Table 1 , pretreatment with IL-la on days -4 and -2 resulted in a significantly higher survival rate in mice ip injected with LPS (S. typhosa). The 50% lethal dose (LD50) of LPS was approximately threefold higher in IL-la pretreated mice than in untreated mice. However, such an effect was not observed with OK-432 pretreatment.
We next examined a more effective administration of IL-la. IL-la was administered on day -6 or -2, or on days -6 and -2 before LPS injection, and the survival rates were 60% (6/10), 80% (8/10), 100% (10/10), respectively, and 20% (2/10) in untreated mice. Since administration of IL-la on days -6 and -2 resulted in the highest survival rate , IL-1 a was administered twice on days -6 and -2 in the following experiments .
In order to know whether the protective effect on LPS-lethality would also be observed with other BRMs, the effects of IL-2, IFN-a, IFN-y, LNT or SPG were examined. As shown in Exp. 1 of Table 2 , a significantly higher survival rate was only observed with IL-la under the conditions employed here. We then examined the effects of IL-1/3 or TNFa on LPS-lethality, because these two BRMs have been reported to have similar biological activities to IL-la (Le and Vilcek Table 2 , IL-1f (1 1cg) showed the protective effect as strong as IL-la (11ug). Concerning the TNFa, the enhanced protective effect was observed with 5 x 103 U/mouse, but not with a higher dose of 1 x 104 U/mouse. Then, we examined whether the enhanced protection to bacterial infection could be observed with TNF a under the same condition as the enhanced protection to LPS was observed. As shown in Exp. I of Table 3 , the enhanced protection to K. pneumoniae infection was not observed with TNF a under the condition in which the enhanced pretection to LPS was observed. Therefore, we did the additional experiment in which TNF a 1 X 104 U/mouse was given once ip 6 hr before infection. No enhanced protection was observed.
Studies on mechanisms for the enhanced protection to LPS-lethality by IL-la In order to discover the mechanisms for the enhanced protection to LPSlethality by IL-1 a, following two possible mechanisms were studied.
Corticosterone level in the serum
It is well known that glucocorticoids exhibit an anti-shock effect, and recently several investigators have reported that IL-1 has an activity to stimulate the release of glucocorticoids (Bernton et al. 1987 ; Sapolsky et al. 1987 ). Therefore, we firstly examined the possibility that a higher level of corticosterone, which is a main endogenous glucocorticoid in the mouse, would be induced after LPS injection in IL-la pretreated mice in contrast to untreated mice. We measured serum corticosterone levels serially 0, 1, 3, 6 and 12 hr after i.p. injection of LPS (2001ug), and compared them between IL-la pretreated and untreated groups. As shown in Fig. 2 , serum corticosterone level rapidly rose after LPS injection and it lasted until 12 hr. However, there was no significant difference in serum corticosterone levels between the two groups. 
Clearance of LPS from serum
We next hypothesized that more rapid clearance of LPS from the serum might occur in IL-la pretreated mice than in untreated mice. In order to investigate this possibility, we measured the levels of LPS in serum serially 1, 3, 6 and 12 hr after i.p. injection of LPS (200 ,u g). As shown in Fig. 3 , the serum LPS levels were significantly lower in IL-1a pretreated mice than in the untreated mice at the points of 3 and 6 hr.
We then examined whether the enhanced clearance of LPS from serum might be partly due to the enhanced LPS-neutralizing activity in serum as reported by Riveau et al. (1987) in rabbits. Therefore, we employed the same method of LAL assay to see whether this would be the case in our mouse system. To quantify the degree of inhibitory activity in sera, we plotted the dose of LPS needed to produce a 50% LAL-gelation response (LR50 ). As shown in Fig. 4 , the LR50 in sera from IL-1c and untreated mice was 290.0 and 31.5 ng/ml, respectively. Significantly stronger LPS-neutralizing activity was observed in the serum from IL-la pretreated mice. The enhanced LPS-neutralizing activity was also observed in the serum from TNFa pretreated mice (data not shown).
DISCUSSION
We compared the protective capabilities of IL-la to bacterial infection and LPS-lethality with other BRMs in mice. OK-432 was shown to have the protective activity to bacterial infection, TNFa to LPS-lethality, and IL-la to both bacterial infection and LPS-lethality.
As far as we examined in the study, only IL-1 among the BRMs had both activities. Although various doses, intervals or routes of administration will be required to reach a conclusion about the protective capabilities of BRMs, concerning the OK-432, IFNa or IFNy, we employed the dosages which had been proved by us to be something in vivo (Mizushima et al. 1988 ). One disagreement with previously published works by others was that TNFa pretreatment did not protect against a bacterial challenge. As Nakano et al. (1990) recently reported, the dose of TNF and the interval between TNF administration and bacterial challenge may be very critical for obtaining the enhancement of host resistance. We suppose that the protective capability of TNFa to bacterial infection should be much weaker than that of IL-la if TNFa has. Anyway, it was suggested from the data with OK-432 and TNFa that mechanisms responsible for host resistance to bacterial infection might be different from those to LPS-lethality.
The phenomenon that IL-1 induces resistance to LPS-lethality has been documented by several investigators, and a few possible mechanisms have been proposed (Riveau et al. 1987; Vogel et al. 1988; Wallach et al. 1988 ). The development of enhanced resistance to LPS-lethality could be theoretically due to 1) an increased secretion of anti-shock substances ; i.e., glucocorticoids, etc. 2) a change in the clearance of LPS. 3) a decreased elaboration of endogenous mediators to induce a shock state ; i.e., TNF, IL-1, etc., in response to LPS, 4) desensitisation of responding cells to endogenous mediators of inflammation, for example by down-regulation of receptors. IL-1 is reported to stimulate the release of glucocorticoids (Bernton et al. 1987; Sapolsky et al. 1987) , and glucocorticoids are well known to have an anti-shock activity. Therefore, we firstly investigated the first possibility that higher levels of glucocorticoids in-duced by IL-la treatment would exert some beneficial effects on LPS-lethality. However, we could not demonstrate any difference in serum corticosterone levels after LPS injection between the mice pretreated with IL-la and the untreated mice (Fig. 2) . Then we next examined the second possibility. We could demonstrate that pretreatment with IL-la resulted in more rapid clearance of LPS from serum after i.p. injection of LPS, and that the serum from IL-1a treated mice contained stronger LPS-neutralizing activity than that from untreated mice. The enhanced neutralization of LPS in the serum was suggested to be partly responsible for the enhanced clearance of LPS in vivo. Riveau et al. (1987) had already reported the enhanced LPS-neutralizing activity in serum from IL-1 treated hosts in rabbits. However, the enhanced clearance of LPS from serum ( Fig. 3) had not been yet demonstrated by any other investigators. We have not at present identified what substances in the serum could be responsible for the neutralization of LPS. We speculate that acute phase proteins may have something to do with the neutralization.
Because Warren et al. (1985) showed that serum from patients with inflammatory states neutralized ten-fold more LPS than that from normal controls. In addition, IL-1 is known to induce the production of acute phase proteins (Dinarello 1986 ). As for the third and fourth possibilities, we have not investigated them yet.
IL-1 is known to have a variety of biological activities and much attention has been paid to its effects on antibacterial resistance (Ozaki et al. 1987; Meer et al. 1988; Minami et al. 1988 ) and hematopoiesis (Jubinsky and Stanley 1985; Moore and Warren 1987) . These two biological activities seem most beneficial for its application to cancer treatment. IL-1 may be of clinical value for protecting cancer patients having intensive chemotherapy from life-threatening infections and subsequent endotoxin shock.
